Evidence map›Paper›PMID 37226238›Full record

ArticleBMC biology2023

CCP5 and CCP6 retain CP110 and negatively regulate ciliogenesis.

Yujuan Wang, Yuan Zhang, Xinyu Guo, Yiqiang Zheng, Xinjie Zhang, Shanshan Feng, Hui-Yuan Wu

Open access · goldAbstract read
In one paragraph

Article in BMC biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yujuan Wang *School of Pharmaceutical Science and Technology, Tianjin University, 92 Weijin Road, Building 24, Room 417-8, Tianjin, 300072, China.
Yuan Zhang *School of Pharmaceutical Science and Technology, Tianjin University, 92 Weijin Road, Building 24, Room 417-8, Tianjin, 300072, China.
Xinyu GuoSchool of Pharmaceutical Science and Technology, Tianjin University, 92 Weijin Road, Building 24, Room 417-8, Tianjin, 300072, China.
Yiqiang ZhengSchool of Pharmaceutical Science and Technology, Tianjin University, 92 Weijin Road, Building 24, Room 417-8, Tianjin, 300072, China.
Xinjie ZhangSchool of Pharmaceutical Science and Technology, Tianjin University, 92 Weijin Road, Building 24, Room 417-8, Tianjin, 300072, China.
Shanshan FengKey Laboratory of Regenerative Medicine, Ministry of Education, Department of Developmental and Regenerative Biology, Jinan University, Guangzhou, 51063, China.
Hui-Yuan WuSchool of Pharmaceutical Science and Technology, Tianjin University, 92 Weijin Road, Building 24, Room 417-8, Tianjin, 300072, China. huiyuan.wu@tju.edu.cn.ORCID 0000-0002-5586-8857
Tianjin University · CNJinan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe axonemal microtubules of primary cilium undergo a conserved protein posttranslational modification (PTM) - polyglutamylation. This reversible procedure is processed by tubulin tyrosine ligase-like polyglutamylases to form secondary polyglutamate side chains, which are metabolized by the 6-member cytosolic carboxypeptidase (CCP) family. Although polyglutamylation modifying enzymes have been linked to ciliary architecture and motility, it was unknown whether they also play a role in ciliogenesis.

resultsIn this study, we found that CCP5 expression is transiently downregulated upon the initiation of ciliogenesis, but recovered after cilia are formed. Overexpression of CCP5 inhibited ciliogenesis, suggesting that a transient downregulation of CCP5 expression is required for ciliation initiation. Interestingly, the inhibitory effect of CCP5 on ciliogenesis does not rely on its enzyme activity. Among other 3 CCP members tested, only CCP6 can similarly suppress ciliogenesis. Using CoIP-MS analysis, we identified a protein that potentially interacts with CCP - CP110, a known negative regulator of ciliogenesis, whose degradation at the distal end of mother centriole permits cilia assembly. We found that both CCP5 and CCP6 can modulate CP110 level. Particularly, CCP5 interacts with CP110 through its N-terminus. Loss of CCP5 or CCP6 led to the disappearance of CP110 at the mother centriole and abnormally increased ciliation in cycling RPE-1 cells. Co-depletion of CCP5 and CCP6 synergized this abnormal ciliation, suggesting their partially overlapped function in suppressing cilia formation in cycling cells. In contrast, co-depletion of the two enzymes did not further increase the length of cilia, although CCP5 and CCP6 differentially regulate polyglutamate side-chain length of ciliary axoneme and both contribute to limiting cilia length, suggesting that they may share a common pathway in cilia length control. Through inducing the overexpression of CCP5 or CCP6 at different stages of ciliogenesis, we further demonstrated that CCP5 or CCP6 inhibited cilia formation before ciliogenesis, while shortened the length of cilia after cilia formation.

conclusionThese findings reveal the dual role of CCP5 and CCP6. In addition to regulating cilia length, they also retain CP110 level to suppress cilia formation in cycling cells, pointing to a novel regulatory mechanism for ciliogenesis mediated by demodifying enzymes of a conserved ciliary PTM, polyglutamylation.

Indexed as

CarboxypeptidasesCiliaMicrotubule-Associated ProteinsCell Cycle ProteinsHEK293 CellsHumansMicrotubulesPhosphoproteinsAGBL4 protein, humanAGBL5 protein, humanCarboxypeptidasesCCP110 protein, humanCell Cycle ProteinsMicrotubule-Associated ProteinsPhosphoproteinsCCP5CCP6CiliogenesisCP110Polyglutamylation

Identifiers

PMID37226238
PMCPMC10210458
OpenAlexW4378173169

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.